Nov 24, 2020

For Immediate Release November 24, 2020

Montreal, Canada – (ACCESSWIRE) – Sunshine Biopharma Inc. (OTC Pink: “SBFM”), a  pharmaceutical company focused on the research, development and commercialization of  oncology and antiviral drugs today announced that it is pushing ahead with its Anti-Coronavirus  drug development program. While the recent announcements about effective vaccines on the 

horizon is a cause for celebration, Sunshine Biopharma believes that a treatment for  Coronavirus infections continues to be essential for any robust healthcare system. This is  particularly important in view of the fact that gaps and lapses will likely occur during vaccine  implementation and people may fall ill and require treatment. In addition, a treatment that can be  taken orally at home, much like an antibiotic, would be an ideal complement for vaccination. 

“SARS-CoV-2, the causative agent of COVID-19, is the third in a line of Betacoronaviruses that  have caused serious human health threats in the past. The first two were SARS-CoV that  appeared in 2002 and MERS-CoV in 2015,” said Dr. Steve N. Slilaty, CEO of Sunshine  Biopharma. “There is nothing that says that another Betacoronavirus with a potential for causing  yet another serious threat to human health won’t appear in the future. It is critical for us to have  a treatment for today and as part of our preparedness for the future,” he added. 

About Sunshine Biopharma’s Coronavirus Treatment 

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of  COVID-19, the current ongoing pandemic that has claimed the lives of over 1.3 million people  worldwide since it first appeared in December 2019. There are currently no drugs that can  effectively arrest replication of the virus in people who have contracted the illness. On May 22,  2020, Sunshine Biopharma filed a provisional patent application for a library of molecules which  were designed to inhibit the Coronavirus proteases, thus shutting down the ability of the virus to  multiply and cause illness. Sunshine Biopharma has since screened the library and identified a  lead Anti-Coronavirus compound (SBFM-PL4). The Company is currently conducting a series of  in vitro tests to evaluate its specific inhibitory activity of SBFM-PL4 against the SARS-CoV-2  papain-like protease (PLpro), one of two Coronavirus encoded proteases essential for viral  replication. Following the initial in vitro studies, SBFM-PL4 will be moved forward to the cell  culture testing stage and assessment in Coronavirus infected mice before entering human  clinical trials.

About Sunshine Biopharma 

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is  engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to  date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant  Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer  cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to  be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine  Biopharma is owner of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ  materially from those anticipated or expected, including statements related to the amount and timing of expected  revenues statements related to our financial performance, expected income, distributions, and future growth for  upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by  the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain  events could differ materially from those projected in or contemplated by the forward-looking statements due to a  number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not  be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock  market conditions. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC  filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as  new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the  near and long term. Additional service offerings may expose us to additional legal and regulatory costs and  unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of  which cannot be predicted at this time. 

For Additional Information: 

Sunshine Biopharma, Inc. 

Camille Sebaaly, CFO 

Direct Line: 514-814-0464